Get the latest tech news
New treatment eliminates bladder cancer in 82% of patients
LOS ANGELES — A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment. In the majority of cases, the cancer disappeared after only three months of treatment, and almost half the patien...
The disease is considered high risk when, depending on the type and location of the tumors, the cancer carries a higher chance of recurrence and/or spreading to the bladder muscles or other parts of the body. The standard treatment for this type of bladder cancer is an immunotherapy drug, Bacillus Calmette-Guérin, which may be ineffective in a percentage of patients. This clinical trial is one of several ongoing ones investigating the effect of TAR-200 and the slow release of cancer-fighting drugs into the bladder to fight cancer.
Or read this on Hacker News
